جستجوی مقالات مرتبط با کلیدواژه "lactobacillus reuteri" در نشریات گروه "پزشکی"
-
Background
Regarding the appropriate effect of probiotics in treating acute diarrhea and the high prevalence of non-bacterial acute diarrhea among children in the population.
ObjectivesThe present study evaluates the effect of synbiotic drops in children with acute diarrhea, including the number of hospitalization days, daily excreted diarrhea volume, duration of diarrhea, and reduction in the number of excretions between the case and control groups.
MethodsThis was a prospective double-blinded and randomized-controlled clinical trial on children aged 6 - 24 months with non-bloody acute diarrhea were included. The reason for hospitalization was diarrhea. In the case group, the patients consume PediLact (Zisttakhmir, Tehran, Iran) drop ( Lactobacillus rhamnosus , Lactobacillus reuteri , and bifidobacterium infantis ) 10 9 CFU and fructooligosaccharides. PediLact drop was used with milk or lukewarm food for five days along with other routine hospital cares. The number of hospitalization days, the daily excreted diarrhea, diarrhea duration, and decreasing numbers of excretion in patients were compared.
ResultsIn the current study, 114 children were included. The duration of hospitalization was 3.87 ± 0.9 days in the synbiotic group and 4.26 ± 0.12 days in the placebo group (P-value = 0.001). The time between the onset of diarrhea and recovery was significantly higher in the placebo group than in the synbiotic group (P = 0.032). The number of evacuations was 1.89 ± 0.13 in the synbiotic group and 2.52 ± 0.18 in the placebo group (P = 0.014).
Keywords: Bifidobacterium Infantis, Lactobacillus Rhamnosus, Lactobacillus Reuteri, Diarrhea -
Background and Objectives
Human herpes virus type 1 (HSV-1) is a neurotropic pathogen that is infected more than 70% of the world population. The increasing of viral resistance to antiviral drugs and the emergence of side effects has motivated researchers to study the use of probiotics as new antiviral agents. The aim of the present study was to study for the first time the potential antiviral activity of Lactobacillus reuteri (L. reuteri) supernatant against HSV-1.
Materials and MethodsAfter measuring the cytotoxicity of L. reuteri supernatant by MTT assay, 1:16 dilution of it was added to HeLa cells before and after HSV-1 infection, after 1.5 hours incubation with HSV-1, and simultaneously with HSV- 1 infection. After 48 hours of incubation at 37°C, the viral titer and expression levels of UL54, UL52 and UL27 genes were measured by tissue culture infectious dose 50 (TCID ) and Real-Time PCR methods, respectively.
ResultsHSV-1 titer in the treatment conditions before infection, incubation with HSV-1, simultaneously with infection and after infection was reduced by 0.42, 3.42, 1.83, and 0.83 log 10 TCID /ml, respectively. When the bacterial supernatant was first incubated with the virus and then added to the cell, or when it was added simultaneously with the virus, the expression of the UL27, UL52, and UL54 genes decreased significantly (p<0.05). When the bacterial supernatant is added to the cell before or after virus infection, the expression of UL52 and UL54 genes does not change significantly (P>0.05).
ConclusionThe study findings indicated that the supernatant of L. reuteri has a potent anti-HSV-1 effect especially if it is incubated with the virus before inoculation into the cell. Its possible antiviral mechanism is to inhibit the virus by binding to it or changing the surface structure of the virus. Metabolites of L. reuteri can be considered as a novel inhibitor of HSV-1in- fection.
Keywords: Antiviral, Cell culture, Lactobacillus reuteri, Herpes simplex virus type 1 -
The infant gut undergoes significant developmental phases that are fully dependent upon the colonization with microorganisms, beginning at birth. This colonization of gut microbiota has a powerful impact on host metabolic and immune homoeostasis. Probiotics strains exhibit a wide range of health benefits by modifying the intestinal microbiota and immunity. Lactobacillus reuteri is one of the most extensively studied probiotic strains. It promotes gut health by stimulation of mucosal gut barrier functions, production of antimicrobial substances (such as reuterin and lactic acid) and influencing acquired and innate immune responses. Reuterin produced by L. reuteri is a potent anti-microbial compoundcapable of inhibiting a wide spectrum of pathogenic microorganisms. Apart from antimicrobial metabolite production, L. reuteri creates biofilms that stimulate tumor necrosis factor production by lipopolysaccharide (LPS)- activated monocytoid cells. Interestingly, L. reuteri administration has emerged as a potential therapy for childhood functional gastrointestinal disturbances as these disturbances are associated with gut microbiota perturbations in early life. The current review summarizes the beneficial aspects of the probiotic L. reuteri strain in clinical practice with a special focus on its role in improving gut health and immunity in infants and toddlers.
Keywords: Lactobacillus reuteri, Probiotics, Gut health, Immunomodulation, Infants -
Background and Objectives
Probiotics are added into the food or feed systems and provide beneficial effects to the human or animal health. This study aimed to isolate the gastrointestinal native Lactobacillus strains with high probiotic, cholesterol-assimilation and aflatoxin-degradation capabilities from native chickens.
Materials and MethodsAbout 70 Lactobacillus isolates were isolated from ileum of the Fars province native chickens and were investigated for their probiotic properties.
ResultsOf 70 Lactobacillus isolates, 10 showed high probiotic capabilities, including survival at acidic conditions (pH up to 2.5), tolerance of 0.5% bile and 6-10% NaCl salts, growth in a wide range of temperature from 15 to 45°C, antagonistic effects against different important bacterial pathogens (Pseudomonas aeruginosa, Escherichia coli, Streptococcus mutans, Clostridium defficile, Enterococcus hirae, Salmonella enterica and Staphylococcus aureus) and sensitivity to some important antibiotics. The selected strains had an aggregation time less than 120 min. The 16S-rDNA sequencing showed that the selected strains were highly related to Lactobacillus reuteri and L. casei. Finally, the selected strains in this study along with 10 other probiotic strains isolated and characterized in our pervious study were used to evaluate their cholesterol assimilation and aflatoxin B1 degradation capabilities. The potentials of cholesterol assimilation of the selected strains were significantly different (P<0.05) and ranged from 2.3% to 99%. The highest content of cholesterol assimilation was obtained in isolates M20 and M4 with more than 98% absorption. Moreover, four strains 43, OR7, M21 and OR9 were able to absorb AFB1 with 58.6%, 52.33%, 47% and 31.6% efficiency respectively.
ConclusionIt could be concluded that the strains 43, M21 and OR7 showed high probiotic potentials for application in the poultry industry.
Keywords: Probiotics, Aflatoxin B1, Cholesterol, Lactobacillus reuteri, Lactobacillus casei, Poultry -
Background
Wound healing is a complex and overlapping process involving immune cells, cytokines, and growth factors.
ObjectivesThis study aimed to design and evaluate a novel wound dressing based on postbiotic/chitosan in accelerating wound healing.
MethodsLactobacillus reuteri PTCC1655 was cultured, and the cell-free supernatant (postbiotic) was obtained by medium centrifugation. The films were prepared using the solvent casting method and evaluated in terms of water absorption index, water vapor transmission rate, and antimicrobial properties. Forty-five male Wistar rats were subjected to a full-thickness excisional wound to assess the wound healing potential. The rats were randomly divided into ctrl-, chitosan, and postbiotic groups. The time-course histological and gene expression analysis was performed to compare the dressing efficacy.
ResultsThe films showed proper water absorption and water vapor transmission rate and inhibited the pathogens commonly associated with wound infection. The postbiotic film improved wound healing by modulating the inflammatory phase, increasing collagen and elastin deposition, and enhancing angiogenesis based on the histological results. The gene expression assay showed that the postbiotic film accelerated wound healing by improving the expression of inflammatory mediators (IL-6 and TNF-α) and anti-inflammatory mediators (TGF-β and VEGF).
ConclusionsThe cell-free supernatant/chitosan/polyethylene glycol (CFS/CS/PEG) biodegradable film could be introduced as a novel dressing for cutaneous wound healing. This transparent film enhances cutaneous wound healing by modulating infiltrated immunity cells and expressing inflammatory/anti-inflammatory cytokines.
Keywords: Wound Healing, Postbiotic, Chitosan, Lactobacillus reuteri -
سابقه و هدف
لاکتوباسیلوس روتری، اثراتی با طیف گسترده در برابر باکتری های گرم مثبت و منفی؛ و همچنین قارچ ها و تک یاخته ها دارد. کومارین ها از توانایی بالا برای مهار و درمان سرطان برخوردار هستند. آپوپتوز، مرگ برنامه ریزی شده سلولی می باشد که در رشد و نمو و هموستازی موجودات زنده نقش اساسی ایفا می کند. ژن Bax و Bcl2 از جمله ژن های کلیدی در مسیر داخلی آپوپتوز می باشند و این مطالعه به منظور تعیین اثر کومارین و لاکتوباسیلوس روتری بر بیان ژن های آپوپتوزیBax وBcl2 بر رده ی سلولی AGSانجام شد.
مواد و روش هاپس از کشت سلول های سرطان معده، کومارین و لاکتوباسیلوس روتری در غلظت های مختلف بر این سلول ها تاثیر داده شد و اثر مهارکنندگی بر تکثیر سلولی با استفاده از روش (MTT) مورد ارزیابی قرار گرفت. RNA سلول ها با استفاده از کیت استخراج RNA تخلیص شد و در نهایت پس از ساختcDNA، بیان دو ژن مرتبط با آپوپتوز با واکنش Real time PCR تعیین گردید.
نتایجنتایج حاصل از روش MTT بر سلول های سرطان معده، خاصیت مهارکنندگی کومارین و لاکتوباسیلوس روتری را نشان داد. همچنین نتایج حاصل از آزمون Real time PCR مشخص کرد که میزان بیان ژن Bax و Bcl2 در مقایسه با گروه کنترل افزایش معنی داری داشته است.
نتیجه گیریبا توجه به اثرات کومارین و لاکتوباسیلوس روتری در مهار تکثیری سلول های AGSو افزایش ژنBax وBcl2 می توان نتیجه گرفت که کومارین و لاکتوباسیلوس روتری می توانند با تاثیر بر بیان ژن های دخیل در آپوپتوز موجب القای آپوپتوز در سلول های سرطانی شوند.
کلید واژگان: سرطان معده, لاکتوباسیلوس روتری, کومارینFeyz, Volume:24 Issue: 2, 2020, PP 122 -132BackgroundLactobacillus reuteri has broad-spectrum effects on both gram-positive and negative bacteria as well as fungi and protozoa. Also, Coumarins have high ability to control and treat cancer. Apoptosis is a planned cell death that plays an essential role in the development and homostasis of living creatures. Bax and Bcl2 genes are among key target genes of internal pathway; thus the present study aimed to determine the effect of L. reuteri and Coumarin on the expression of these two genes on AGS cell line.
Materials and MethodsAfter cultivation of gastric cancer cells, Coumarin and L. reuteri were affected in these concentrations at different concentrations and the inhibitory effect on cell proliferation was evaluated using the MTT method. Afterwards, the RNA content of cells was extracted using an RNA extraction kit. Then the cDNA was synthesized for Bax and Bcl2 genes and finally Real time PCR was run.
ResultsThe results of the MTT assay on gastric cancer cells showed the inhibitory effect of Coumarin and L. reuteri. Also, the results of Real Time PCR showed that the expression of Bax and Bcl2 expression in comparison with the control group was significantly increased.
ConclusionConsidering the effects of Coumarin and L. reuteri on inhibiting proliferation of AGS cells and increasing the Bax and Bcl2 gene, it can be concluded that Coumarin and L. reuteri can induce apoptosis in cancerous cells by affecting the expression of genes involved in apoptosis.
Keywords: Stomach cancer, Lactobacillus reuteri, Coumarin -
The infantile colic is one of the most common complaints in the infancy; however, limited therapeutic approaches are described in the literature. Recently probiotics have been suggested as a potential strategy in the treatment of infantile colic. We conducted this study to investigate the efficacy of probiotics in relieving colic symptoms in Iranian infants. This double-blind clinical trial was performed among 70 infants aged 3 to 16 weeks with the presumed diagnosis of infantile colic according to Wessel criteria who were breastfed or formula fed. They were assigned at random to receive Pedilact® (Bifidobacterium infantis, Lactobacillus reuteri, and Lactobacillus rhamnosus) (N=33) or placebo (N=32). Demographic data were recorded in the questionnaires at the beginning of the study. The number of daily episodes of crying and fussiness, number of weekly crying days, and duration of crying were separately analyzed on 7, 21, and 30th days of investigation. Baseline demographic data showed no statistically significant difference between intervention and placebo groups. Infants given Pedilact® showed a significant reduction in daily episodes of crying, duration of crying, and the weekly number of crying days at the end of the treatment period compared with those receiving placebo (P=0.000). On 21th day of the study, daily episodes of fuss and crying (P=0.032) and duration of crying reduced significantly in the intervention group in comparison to the placebo group (P=0.000). Administration of Pedilact® drop significantly improved colic symptoms by reducing crying and fussing times in breastfed or formula fed in Iranian infants with colic.
Keywords: Bifidobacterium infantis, Infantile colic, Lactobacillus reuteri, Lactobacillus rhamnosus, Probiotics -
Background
The present study aimed to determine the antimicrobial effects of Lactobacillus acidophilus and Lactobacillus reuteri against Campylobacter jejuni in fresh and roasted chicken breast fillets.
MethodsFresh and roasted chicken breast fillets were soaked in probiotic suspensions (11 log CFU/ml) and immersed in C. jejuni suspension (5 and 3 log CFU/ml). Afterwards, the fillets were placed in clean stomacher bags and refrigerated for 10 days until further analysis.
ResultsThe count of 5 log CFU/g in the fresh fillets treated with L. acidophilus, L. reuteri, L. reuteri, and L. acidophilus reached 3.45, 3.89, and 4.25 log CFU/g after 10 days of refrigerated storage, respectively. In the roasted fillets, the corresponding counts were estimated at 2.99, 3.54, and 3.92 log CFU/g, respectively. In addition, the inoculated 3 log CFU/g of C. jejuni reached 1.09-1.11 log CFU/g after the refrigerated storage of the fresh and roasted chicken breast fillets.
ConclusionAccording to the results, the addition of L. acidophilus and L. reuteri to the fresh and roasted chicken breast fillets had inhibitory effects against the growth of C. jejuni.
Keywords: Campylobacter jejuni, Lactobacillus acidophilus, Lactobacillus reuteri -
BackgroundColorectal cancer (CRC) is the third and a second common cancer in men and women respectively in the world and about 1.4 million new cases diagnosed in 2012. The normal gut microflora consists of bacterial species. One group of them is probiotics, which confer a health benefit to the host. Lactobacillus reuteri (L.reuteri) is known as a probiotic, which lead to the prevention of colorectal cancer. The aim of this study was to assess the inhibitory effects of Lactobacillus reuteris cell wall on cell proliferation in the colorectal cancer HCT-116 cell line.Materials And MethodsThe cells of HCT-116 cell line were grown at 37°C, 5% CO2. L.reuteri was obtained from the Iranian Biological Resource Center and cultured in the MRS Broth at 37°C for 48h anaerobically. The cell wall was prepared by the freezing-thawing procedure. So the inhibitory effect of L.reuteri on the growth and proliferation of HCT-116 cells was assessed by MTT assay.ResultsThe cell wall from L.reuteri inhibited cell proliferation on colorectal cancer HCT-116 cell line. It showed dose- and time dependent inhibition.ConclusionThese results demonstrated that cell wall of L.reuteri inhibits cell proliferation of HCT-116 cell line.Keywords: Colorectal cancer, Lactobacillus reuteri, HCT-116 cell line
-
IntroductionWith due attention to the relationship between bacterial vaginosis and urinary tract infection and treatment of gynecologic problems occur when a high recurrence of bacterial vaginosis is often treated with antibiotics. The purpose of this study is to inhibitory effect of Lactobacillus rhamnosus and Lactobacillus reuteri on E.coli isolated from women with bacterial vaginosis.Methods96 samples from women with bacterial vaginosis discharge referred to health centers department Shahid Beheshti University in 91-92 were taken with a dacron swab and put in sterile tubes containing TSB and thioglycollate broth. Afterward, culture was transferred on blood agar, EMB, Palcam and Differential diagnosis environments. Strains of Lactobacillus rhamnosus and Lactobacillus reuteri were cultured in MRS environment and were transferred to the lab. After purification of E.coli, inhibitory effect of Lactobacillus rhamnosus and Lactobacillus reuteri on E.coli is checked. Statistical analysis was performed using SPSS software v.16.ResultsThe results of this study demonstrate inhibitory effect of Lactobacillus rhamnosus and Lactobacillus reuteri on Ecoli that is one of the causes bacterial vaginosis is 20% and 30%, respectively.ConclusionsOur findings indicated the little inhibitory effect of Lactobacillus rhamnosus and Lactobacillus reuteri on E.coli that is one of the cause bacterial vaginosis. The results of this study, the hypothesis that inhibit the growth of this Gram-negative pathogen causing bacterial vaginosis is not supported by probiotics.Keywords: Lactobacillus Rhamnosus, Lactobacillus Reuteri, Vaginosis, Bacterial, Probiotics
-
BackgroundLactobacillus reuteri is a probiotic that originated from humans and have been used for eradication of the Helicobacter pylori (HP) infection.ObjectivesThis study was aimed to determine whether adding probiotics to a triple regimen against HP could improve the eradication rate.MethodsIn a double-blind randomized clinical trial in Iran between October 2012 and January 2014, all eligible patients (Fifty HP positive children, 5 - 14 years old, mean age: 8.5 2.5 years, Male/female: 17/33) were entered into the study based on the convenience sampling method and random selection. An endoscopy was performed on all patients and the subjects received antibiotics as well as proton pomp inhibitors with or without the probiotic (Lactobacillus reuteri) in two separate groups. Four weeks after the end of treatment (discontinuation of all medicine) a urea breath test was performed in both groups in order to evaluate eradication of the HP infection.ResultsEradication rate in the group that received Lactobacillus reuteri was 88% compared to the group that was treated with standard Helicobacter pylori regimen (76%). This study showed the eradication rate of the probiotics group was 12% higher than the control group, although it was not significant (P = 0.46). Furthermore, results of this study showed a reduction of symptoms before and after treatment in both groups, although the difference between two groups was not significant.ConclusionsThere was no significant effect of Lactobacillus reuteri on the eradication of Helicobacter pylori compared to the standard group. More research in this regard is recommended.Keywords: Children, Lactobacillus reuteri, Helicobacter pylori
-
پیش زمینه و هدفطبیعت منحصربه فرد لیستریا مونوسیتوژنز و توانایی رشد در درجه حرارت های یخچالی، لیستریا مونوسیتوژنز را به یک تهدید جدی برای ایمنی محصولات گوشتی آماده مصرف تبدیل کرده است. مشخص شده است که باکتری های اسیدلاکتیک در مهار لیستریا مونوسیتوژنز در فراورده های گوشتی ازجمله گوشت تازه و پخته موثر می باشند. پری بیوتیک ها در بسیاری از مواد غذایی ازجمله سیر وجود دارند که رشد لاکتوباسیلوس ها را تحریک می کنند. هدف این مطالعه استفاده از لاکتوباسیلوس روتری همراه با عصاره آبی سیر در کنترل رشد لیستریا مونوسیتوژنز می باشد.مواد و روش کارابتدا اثر تحریکی عصاره آبی سیر بر رشد لاکتوباسیلوس روتری در سه غلظت مختلف (50، 100 و 200 میلی گرم بر میلی لیتر) بررسی شد. سپس اثر مهاری لاکتوباسیلوس روتری همراه با عصاره آبی سیر علیه لیستریا مونوسیتوژنز در مدت زمان صفر، 4، 8 و 24 ساعت مورد ارزیابی قرار گرفت.یافته هانتایج حاصل از این مطالعه نشان داد که دو غلظت (100 و 200 میلی گرم بر میلی لیتر) عصاره آبی سیر بیشترین اثر تحریکی را بر روی رشد لاکتوباسیلوس روتری داشت. همچنین لاکتوباسیلوس روتری همراه با عصاره آبی سیر به طور موثر رشد پاتوژن لیستریا مونوسیتوژنز را مهار نمود.بحث و نتیجه گیریاستفاده از عصاره آبی سیر همراه با لاکتوباسیلوس روتری اثر مهاری لاکتوباسیلوس علیه لیستریا مونوسیتوژنز را افزایش می دهد.کلید واژگان: لیستریا مونوسیتوژنز, لاکتوباسیلوس روتری, کنترل زیستی, عصاره آبی سیرBackground and AimsThe ubiquitous nature of Listeria monocytogenes and its ability to grow at refrigerated temperature makes L. monocytogenes a serious threat to the safety of ready-to-eat (RTE) meat products. Lactic acid bacteria (LAB) have been found to be effective in inhibiting L. monocytogenes in food products such as fresh and cooked meats. Prebiotics exist in many foodstuffs such as garlic which stimulates the growth of lactobacilli. The aim of this study was to use Lactobacillus reuteri together with aqueous extract of garlic for controlling the growth of Listeria monocytogenes.Materials and MethodsFirst stimulatory effect of water extract of garlic in different concentrations (50, 100 and 200 mg/ml) on the growth of L. reuteri was evaluated. Then, inhibitory effect of L. reuteri along with aqueous extract of garlic against Listeria monocytogenes was investigated for 0, 4, 8 and 24 h.ResultsThe results of this study showed that two concentration (100 and 200 mg/ml) of aqueous extracts of garlic had highest stimulatory effect on Lactobacillus reuteri growth. Also L. ruteri along with garlic extract significantly inhibited the growth of listeria monocytogenes.ConclusionThe application of garlic extract along with lactobacillus ruteri may increase the inhibitory effect of lactobacillus against listeria monocytogenes.Keywords: Listeria monocytogenes, Lactobacillus reuteri, Biological Control, aqueous extract of garlic
-
BackgroundFeeding intolerance is a common problem among premature infants. There is limited information on the safety and effects of oral probiotic supplements, especially products containing Lactobacillus reuteri, and the incidence of necrotizing enterocolitis (NEC) in low birth weight preterm infants. This study aimed to evaluate the effects of Lactobacillus reuteri on the gastrointestinal complications and feeding tolerance in premature infants.MethodsThis randomized triple-blind clinical trial was conducted on 60 premature infants divided into two groups of intervention and placebo. Subjects in the intervention group received one drop/kg of supplementary oral probiotic with 0.5 ml of distilled water, and infants in the placebo group only received 0.5 ml of distilled water. Probiotic administration continued to reach full enteral feeding.ResultsIn this study, mean time to reach full enteral feeding was 12.83 and 16.75 days in the intervention and placebo groups, respectively, which was indicative of a significant difference (P=0.01). However, mean of neonatal weight at discharge had no significant difference between the two groups. In addition, 6.7% and 36.7% of infants in the intervention and placebo groups were diagnosed with NEC, respectively, which showed a significant difference (P=0.005). Also, prevalence of jaundice and sepsis was not significantly different between the study groups.ConclusionAccording to the results of this study, Lactobacillus reuteri could reduce the time to reach full enteral feeding while diminishing the incidence of NEC in very low birth weight premature infants.Keywords: Lactobacillus Reuteri, Necrotizing Enterocolitis, Probiotic, Very Low Birth Weight Infants
-
Glutamate decarboxylase enzyme produces γ-aminobutyric acid (GABA) in a non-reversible decarboxylation reaction of glutamate. GABA is a major inhibitory neurotransmitter of the brain and it is also present at high concentration in other organs such as pancreatic islets. GABA has effects on blood pressure, diabetes, inflammation, sleeplessness and depression. Some bacteria such as Lactobacillus strains are capable of GABA production. Identification of these bacteria is important both for researchers and industry. The aim of this study was molecular gene cloning and sequencing of glutamate decarboxylase (gad) from Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 and Lactobacillus reuteri ATCC 23272. These strains were cultured in MRS medium at 37○C for 24 hours. For cloning gad gene from these strains, polymerase chain reaction (PCR) was performed using specific primers designed by Oligo7 software. PCR production was extracted from agarose gel and was inserted into PGEM-T vector using T4 DNA ligase enzyme and then it was transformed to E. coli XL1Blue. In the final step, white colonies were selected and after plasmid extraction, the existence of gad gene in recombinants was confirmed by PCR. Gad gene was cloned from Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 and Lactobacillus reuteri ATCC 23272. It is for the first time that the gad gene sequences from these bacteria were registered on NCBI with accession numbers KF751355 and KF751352 respectively. The result of this research indicates that the two aforementioned bacteria contain glutamate decarboxylase gene and therefore they possibly can be used for industrial γ-aminobutyric acid production.Keywords: Glutamate decarboxylase, γ aminobutyric acid, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus reuteri
-
BackgroundFunctional abdominal pain (FAP) is one of the most common diseases, and large percentages of children suffer from it.ObjectivesThe purpose of the study was to evaluate the effect of Lactobacillus reuteri in treatment of children with functional abdominal pain. Patients andMethodsThis study was a randomized double-blind placebo-controlled trial. Children aged 4 to 16 years with chronic functional abdominal pain (based on Rome III criteria) were enrolled in the study. They were randomly divided into two groups, one receiving probiotic and the other placebo.ResultsForty children received probiotic and forty others placebo. There were no significant differences in age, weight, sex, location of pain, associated symptoms, frequency and intensity of pain between the groups. The severity and frequency of abdominal pain in the first month compared to baseline was significantly less and at the end of the second month, there was no significant difference between both groups compared to the end of the first month.ConclusionsThis study showed that the severity of pain was significantly reduced in both groups. There was no significant difference in pain scores between them. The effect of probiotic and placebo can probably be attributed to psychological effect of the drugs.Keywords: Lactobacillus reuteri, Functional Abdominal Pain, Children
-
BackgroundUropathogenic Escherichia coli (UPEC) is one of the most common bacteria that can cause urinary tract infections (UTIs). Unfortunately, no human vaccine against UTIs has been developed. Therefore, it is necessary to develop an efficient and safe vaccine that is able to induce mucosal and systemic immune responses. The use of lactic acid bacteria as a delivery system is a promising method to induce the immune system.ObjectivesThe aim of this study was to establish Lactobacillus reuteri harboring the E. coli PapG antigen on its surface.Materials And MethodsIn this study, the gene encoding PapG was fused to the AcmA gene (which encodes an anchor protein in Lactobacillus) and cloned into the pEX A vector. The PapG.AcmA fusion gene was digested with BamHI and NdeI and sub-cloned into the pET21a expression vector at the digestion sites. Subsequently, the recombinant plasmids (pET21a-PapG.AcmA and pET21a-PapG) were transformed into the E. coli Origami strain using the calcium chloride method and the fusion protein was expressed under 1 mM IPTG induction. The expression of the fusion protein was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting. Purification of the PapG and PapG.AcmA proteins was carried out using a Ni-NTA column, and surface adsorption was estimated on Lactobacillus. Finally, surface localization of the fusion protein was verified by an enzyme-linked immunosorbent assay (ELISA).ResultsThe PapG.AcmA fusion was successfully sub-cloned in the pET21a expression vector. The expression of PapG and PapG.AcmA proteins in the E. coli Origami strain was indicated as protein bands in SDS-PAGE and confirmed by western blotting. In addition, the fusion protein was displayed on the surface of L. reuteri.ConclusionsIn conclusion, we developed a method to express the PapG.AcmA protein on the surface of Lactobacillus. This is the first report on the successful application of lactic acid bacteria displaying the PapG.AcmA fusion protein. It will be interesting to determine the immune responses against the PapG protein in near future using this surface display strategy.Keywords: Urinary Tract Infections, Lactobacillus reuteri, E. coli
-
سابقه و هدفقلنج شکمی شیرخوارگی یکی از شکایت های شایع والدین در 3 ماهه اول تولد فرزندشان می باشد. از آنجائیکه میکروفلورای روده این شیرخواران با شیرخواران غیرکولیکی متفاوت است لذا این مطالعه به منظور تاثیر پروبیوتیک ها بر بالانس میکروفلورای روده ای انجام و کاهش زمان بی قراری شیرخواران مبتلا به کولیک انجام شد.مواد و روش هااین مطالعه کارآزمایی بالینی بر روی 44 شیرخوار 60-20 روزه، شیر مادر خوار با وزن تولد بالاتر از 2500 گرم بر اساس تعریف Wessel انجام شد. این شیر خواران دارونما را با بر چسب 1 به مدت 5 روز 5 قطره روزانه و سپس لاکتوباسیل روتری (17938 DSM) با برچسب 2 به مدت 14 روز 5 قطره روزانه دریافت نمودند. روزانه 2 بار با والدین تماس تلفنی گرفته شد و مدت زمان دل پیچه و بی قراری شیرخوار ثبت و ارزیابی شد (IRCT=2014012713489).یافته هااز میان 44 شیرخوار 36 مورد مطالعه را به پایان رساندند. متوسط زمان بی قراری پس از 5 روز دریافت دارو نما و 5 روز دریافت لاکتوباسیل روتری به ترتیب 8 /142±275 دقیقه و 3/ 88±172 بوده p<0.001) و پس از 14 روز مصرف دارو نیز 67/ 53±106 دقیقه شد.نتیجه گیرینتایج مطالعه نشان داد که پروبیوتیک لاکتوباسیل روتری می تواند بر زمان گریه و بی قراری در کولیک شیرخواری موثر باشد.
کلید واژگان: لاکتوباسیل, لاکتوباسیل روتری, کولیک, کولیک شیرخوارگی, پروبیوتیکBackground And ObjectiveAbdominal colic during infancy is a common complaint of parents within the first three months after the child’s birth. As the intestinal microflora in these infants is different from non-colic newborns, we aimed to determine the effects of probiotics on the balance of intestinal microflora and reducing restlessness in infants with colic.MethodsThis randomized clinical trial was performed on 44 breastfed infants (20-60 days old), with a birth weight of > 2500 g, suffering from colic, based on Wessel’s definition. These infants received 1-5 drops of placebo (label 1) per day for five consecutive days. Afterwards, they were administered 2-5 drops of Lactobacillus reuteri (label2) (17938 DSM) per day for 14 consecutive days. The parents were contacted twice on a daily basis and the duration of cramps and restlessness in infants was recorded and evaluated (IRCT=2014012713489).FindingsAmong 44 infants, 36 cases completed the study. The mean period of restlessness after 5 days of receiving placebo and L. reuteri was 275±142.8 and 172±88.3 min, respectively (p<0.001). Also, after 14 days of L. reuteri administration, the mean period of restlessness was 106±53.67 min.ConclusionThe results showed that probiotic L. reuteri reduced crying and restlessness duration in infants with colic.Keywords: Lactobacillus, Lactobacillus Reuteri, Colic, Infant Colic, Probiotic -
Background
Streptococci are the main causative agents in plaque formation and mutans streptococci are the principle etiological agent of dental plaque and caries. The process of biofilm formation is a step-wise process, starting with adhesion of planktonic cells to the surfaces. It is now a well known fact that expression of glucosyltransferases (gtfs) and fructosyltransferase (ftf) genes play a critical role in the initial adhesion of Streptococcus mutans to the tooth surface, which results in the formation of dental plaques and consequently caries and other periodontal diseases.
Materials and MethodsIn the present study, we have determined the effect of biosurfactants purified from Lactobacillus reuteri (DSM20016) culture on gene expression profile of gftB/C and fft of S. mutans (ATCC35668) using quantitative real-time polymerase chain reaction.
ResultsThe application of biosurfactant caused considerable down-regulation of the expression of all three genes under study. The reduction in gene expression was statistically very significant (P > 0.0001 for all three genes).
ConclusionsInhibition of these genes by the extracted L. reuteri biosurfactant shows the emergence of a powerful alternative to the presently practicing alternatives. In view of the importance of these gene products for S. mutans attachment to the tooth surface, which is the initial important step in biofilm production and dental caries, we believe that the biosurfactant prepared in this study could be considered as a step ahead in dental caries prevention.
Keywords: Biosurfactants, Lactobacillus reuteri, oral streptococci, probiotics -
BackgroundConsidering the high prevalence of bacterial vaginosis and its association with urinary tract infection in women and treatment of gynecologic problems occur when a high recurrence of bacterial vaginosis is often treated with antibiotics..ObjectivesThe purpose of this study was to investigate the inhibitory effect of Lactobacillus reuteri on pathogenic bacteria isolated from women with bacterial vaginosis..Materials And MethodsNinety-six samples were obtained from vaginal discharge of women with bacterial vaginosis by a gynecologist with a Dacron swab and put in sterile tubes containing TSB broth and Thioglycollate broth. Then were immediately sent to the laboratory in cold chain for further assessment. Afterward, culture was transferred on blood agar, EMB, Palcam and differential diagnosis environments. Then cultures were incubated for 24 hours at 37 °C. Lactobacillus reuteri strains were cultured in MRS environment and transferred to laboratory. After purification of pathogenic bacteria, Lactobacillus reuteri inhibitory effect on pathogenic bacteria was evaluated by minimum inhibitory concentration (MIC) and antibiogram. Statistical analysis was performed using SPSS software v.16..ResultsThe results of this study demonstrated the inhibitory effect of Lactobacillus reuteri on some pathogenic bacteria that cause bacterial, including Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Enterococcus, Listeria monocytogenes and E. coli. Microscopic examination of stained smears of most Lactobacillus and pathogenic bacteria showed reduced. The prevalence of abnormal vaginal discharge, history of drug use, contraceptive methods and douching were 61%, 55%, 42% and 13%, respectively. Significant difference was observed between the use and non-use of IUD in women with bacterial..ConclusionsOur findings indicated the inhibitory effect of Lactobacillus reuteri on pathogenic bacteria that cause bacterial vaginosis. The results of this study confirmed the inhibitory effect of probiotics on pathogens growth that cause bacterial vaginosis, which can be considered in the prevention and treatment of bacterial vaginosis in further investigations..Keywords: Lactobacillus reuteri, probiotics, bacterial
-
Helicobacter pylori has been associated with colonization of gastro duodenal mucosa of humans from millions of years. The main burden of the disese is in the developing countries, due to overcrowding and poor hygiene. If left untreated it leads to lot of sequlae from minor to sinister diseases over a period of time. The main challenges that remain are prevention of H. pylori-related diseases by effective treatment and screening procedures and development of a vaccine, which can address all these issues including beneficial aspects of H. pylori. The literature pertaining to different aspects of H. pylori were scrutinized from Pubmed. Material on clinical behavior, complications of chronic gastric involvement, and prevention besides role of H. pylori in nongastric diseases and the latest trends of management was collected for research and review. We continue to face many challenges.The prevention of cancer of the stomach, a worst sequlae of H. pylori continues to be a big challenge despite population screening and prevention surveys being underway in many countries. On the other hand continued scientific work has now unfolded involvement of H. pylori in extragastric diseases like cerebrovascular, cardiovascular, idiopathic thrombocytopenia, sideroblastic anemia, mental diseases, and collagen vascular diseases. In contrast, the beneficial effects of H. pylori with respect to allergic diseases and obesity are now clear. Moreover, problem of drug resistance for eradication of H. pylori has arisen for which novel treatments are being tried. Lactobacillus reuteri having anti H. pylori action is emerging as one of the promising treatment.
Keywords: Beneficial aspects, extra gastric diseases, gastric-cancer, its prevention, H. pylori, lactobacillus reuteri, novel clinical behavior, research questions, treatment challenges, vaccination
- نتایج بر اساس تاریخ انتشار مرتب شدهاند.
- کلیدواژه مورد نظر شما تنها در فیلد کلیدواژگان مقالات جستجو شدهاست. به منظور حذف نتایج غیر مرتبط، جستجو تنها در مقالات مجلاتی انجام شده که با مجله ماخذ هم موضوع هستند.
- در صورتی که میخواهید جستجو را در همه موضوعات و با شرایط دیگر تکرار کنید به صفحه جستجوی پیشرفته مجلات مراجعه کنید.